Paper Details

  1. Home
  2. Paper Details

Boosting dose ritonavir does not alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers.

Author: AnthonypillaiJayaranjan, AweekaFrancesca T, GrunfeldCarl, LeeGrace A, MulliganKathleen, PaoVivian Y, SchambelanMorris, SchwarzJean-Marc, TaylorSteven A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.

Overview

Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection. The effects of boosting dose ritonavir (100-200 mg) on glucose metabolism have not been described in the absence of another PI.
Paper Details　
Original Abstract of the Article :
Some HIV protease inhibitors (PIs), including full-dose ritonavir (800 mg) and ritonavir-boosted lopinavir, acutely induce insulin resistance in the absence of HIV infection and changes in body composition. Boosting dose ritonavir (100-200 mg) is the most commonly prescribed PI, yet its effects on g...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/20595906

データ提供：米国国立医学図書館（NLM）

Ritonavir: A Closer Look at its Effects on Insulin Sensitivity

Ritonavir, a protease inhibitor commonly used in HIV treatment, has been shown to induce insulin resistance in some individuals. This study aimed to investigate the effects of boosting dose ritonavir (100-200 mg) on peripheral insulin sensitivity in healthy HIV-seronegative volunteers. The researchers sought to determine whether boosting dose ritonavir, a commonly prescribed regimen, significantly alters glucose metabolism in the absence of other protease inhibitors.

A Deeper Dive into Ritonavir's Effects: No Significant Impact on Insulin Sensitivity

The study found that boosting dose ritonavir did not significantly alter peripheral insulin sensitivity in healthy HIV-seronegative volunteers. This finding suggests that, in the absence of other protease inhibitors, boosting dose ritonavir may not pose a significant risk for inducing insulin resistance. However, the study emphasizes the need for continued monitoring of glucose metabolism in individuals receiving ritonavir-based therapies.

Maintaining Metabolic Balance: A Guide to Ritonavir Therapy

The study's findings provide reassurance regarding the metabolic safety of boosting dose ritonavir in the absence of other protease inhibitors. However, it is important to note that the study involved healthy HIV-seronegative volunteers, and further research is needed to understand the effects of ritonavir in individuals with HIV infection or pre-existing metabolic conditions. Close monitoring of glucose metabolism in patients receiving ritonavir-based therapies remains essential.

Dr.Camel's Conclusion

This study explores the effects of boosting dose ritonavir on insulin sensitivity in healthy individuals. Just as a camel carefully conserves its water resources in the desert, individuals taking ritonavir-based therapies must carefully monitor their metabolic health. The study's findings suggest that boosting dose ritonavir may not pose a significant risk for inducing insulin resistance, but continued monitoring and research are crucial to ensure the safe and effective use of this medication.

Date :
  1. Date Completed 2010-11-04
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

20595906

DOI: Digital Object Identifier

NIHMS221712

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.